NCT04622254 - Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines | Biotech Hunter

Enrollment

368

Participants

Timeline

Start Date

November 12, 2020

Primary Completion Date

June 16, 2021

Study Completion Date

July 8, 2022

Conditions

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Interventions

DRUG

NT 201

Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

DRUG

Placebo

Solution for injection prepared by reconstitution of powder with percent (%) Sodium Chloride (NaCl).

Trial Locations (12)

10707

Merz Investigational Site, Berlin

14467

Merz Investigational Site, Potsdam

20146

Merz Investigational Site, Hamburg

22609

Merz Investigational Site, Hamburg

40212

Merz Investigational Site, Düsseldorf

42287

Merz Investigational Site, Wuppertal

44793

Merz Investigational Site, Bochum

48317

Merz Investigational Site, Drensteinfurt

65182

Merz Investigational Site, Bad Soden

68161

Merz Investigational Site, Mannheim

80539

Merz Investigational Site, München

80636

Merz Investigational Site, München